EspaƱol

The U.S. POINTER-zzz study has been awarded a $5.3 million grant from the U.S. National Institute on Aging (NIA) to incorporate in-home sleep assessments into the Alzheimer’s Association’s clinical trial, the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). U.S. POINTER was a two-year clinical trial that tested whether lifestyle changes can protect cognitive function in people at risk of developing memory decline and dementia.

Chronic sleep disturbances have been linked to an increased risk of cognitive decline and Alzheimer’s disease. Scientific evidence suggests that diet, exercise and cardiometabolic risk reduction can improve sleep, and that improved sleep may benefit cognitive function in older adults. The POINTER-zzz study examined whether lifestyle changes might improve sleep quality in 780 adults who participated in the larger U.S. POINTER clinical trial.

 

U.S. POINTER and Sleep

POINTER-zzz tested whether lifestyle changes could improve sleep using a simple test that is completed at home. The test involved wearing a watch-like device for one or more days and nights to measure sleep apnea, restlessness and other sleep disruptions.

Nearly 65% of participants had at least mild sleep apnea at the start. By the end of the trial, people in the structured program had one to two fewer breathing disruptions per hour of sleep than people in the self-guided program. These results were presented at CTAD 2025. 

Only those enrolled in the U.S. POINTER study were included in the POINTER-zzz sub-study.

Learn more about U.S. POINTER.

"We know that sleep disturbances may cause problems with memory and thinking, and increase the risk for Alzheimer’s-related brain changes. Our hope is that U.S. POINTER-zzz can show us new ways to reduce or eliminate these sleep problems, protect cognitive function and possibly reduce dementia risk."

Maria C. Carrillo, Ph.D., Alzheimer's Association Chief Science Officer and Medical Affairs Lead

Maria C. Carrillo, Ph.D.,
Chief Science Officer and Medical Affairs Lead, Alzheimer's Association